Kojima, Takashi
Kato, Ken
Hara, Hiroki
Takahashi, Shunji
Muro, Kei
Nishina, Tomohiro
Wakabayashi, Masashi
Nomura, Shogo
Sato, Akihiro
Ohtsu, Atsushi
Doi, Toshihiko
Funding for this research was provided by:
Novartis Pharma
Article History
Received: 11 December 2021
Accepted: 30 May 2022
First Online: 29 July 2022
Declarations
:
: Takahashi Kojima has received grants from MSD, Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Astellas Amgen BioPharma, Taiho Pharmaceutical, Chugai Pharmaceutical Co. Ltd., and Shionogi; and honoraria from Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, MSD, Astellas Pharma, Merck, and Oncolys BioPharma. Ken Kato has received grants from Bristol Myers Squibb, Ono Pharmaceutical Co., Ltd., MSD, BeiGene, Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical, AstraZeneca, BAYER, Shionogi, and Novartis; consulting fees from BMS, ONO, and BeiGene; honoraria from Bristol Myers Squibb and ONO; and Participation on advisory board from Daiichi Sankyo. Hiroki Hara has received grants from Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai Pharmaceutical, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Elevar Therapeutics, GSK, Incyte, Merck Biopharma, MSD K. K., Ono, Pfizer, and Taiho Pharmaceutical; consulting fees from Boehringer Ingelheim, Daiichi Sankyo, Dainippon Sumitomo, Lilly, MSD K. K., and Ono; and honoraria from Bayer, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Kyowa Hakko Kirin, Lilly, Merck Biopharma, MSD K. K., Ono, Sanofi, Taiho Pharmaceutical, Takeda, and Yakult Honsha. Shunji Takahashi has received grants from Eisai, Novartis, and Taiho Pharmaceutical; and honoraria from Eisai, Novartis, and Taiho Pharmaceutical. Kei Muro has received all support for the present manuscript from Novartis Pharma K.K.; grants from Astellas, Amgen, Sanofi K.K., Daiichi Sankyo, Parexel International, Taiho, MSD, Merck Biopharma Co., Ltd., Pfizer Inc., Eisai Co., Ltd., Solasia Pharma K.K., and Ono Pharmaceutical Co., Ltd.; consulting fees from Amgen, Ono Pharmaceutical Co., Ltd., and AstraZeneca; honoraria from Eli Lilly, Chugai Pharmaceutical Co. Ltd., Takeda, Ono Pharmaceutical Co., Ltd., Taiho, Sanofi, Bristol Myers Squibb, and Bayer. Tomohiro Nishina has received honoraria from Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo, and Bristol Myers Squibb. Shogo Nomura has received a grant for Amgen, and AstraZeneca; and Honoraria from AstraZeneca, Pfizer, Taiho, and Chugai. Akihiro Sato has received a grant from Novartis pharma. Toshihiko Doi has received grants from Lilly, MSD, Daiichi Sankyo, Sumitomo Dainippon, Taiho, Novartis, Merck Serono, Janssen Pharma, Boehringer Ingelheim, Pfizer, Bristol Myers Squibb, AbbVie, IQVIA, and Eisai; consulting fees from Sumitomo Dainippon, Taiho, Takeda, Chugai Pharmaceutical Co. Ltd. Pharma, AbbVie, Bayer, Rakuten Medical, and Otsuka Pharma; honoraria from Bristol Myers Squibb, Rakuten Medical, Ono Pharma, Oncolys BioPharma, and Taiho; and advises on the boards of MSD, Daiichi Sankyo, Amgen, Novartis, Boehringer Ingelheim, Janssen Pharma, AbbVie, Bayer, and Astellas Pharma. Masashi Wakabayashi and Atsushi Ohtsu report no conflict of interest.
: This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent. The study protocol was approved by the institutional review board at each study site.